Cerebrolysin — EU research guide.

What is Cerebrolysin?

Cerebrolysin is not a single peptide — it is a proprietary mixture produced by enzymatic hydrolysis of purified porcine (pig) brain tissue, containing low-molecular-weight neuropeptides (roughly a quarter by weight) and free amino acids (roughly three-quarters). The peptide fragments are small enough (<10 kDa) to cross the blood-brain barrier. It is manufactured by EVER Neuro Pharma in Austria and is sometimes referred to by the codes FPF-1070 or cerebroprotein hydrolysate.

How is it proposed to work?

Cerebrolysin is described as a multimodal neurotrophic agent, claimed to mimic or modulate endogenous growth factors such as BDNF and NGF. Proposed mechanisms include neuroprotection in acute injury (reducing excitotoxicity, oxidative stress and apoptosis via pathways such as PI3K/Akt) and neurorestoration during recovery (supporting neurogenesis, neuroplasticity and angiogenesis). It is given by injection (IM or IV), not orally.

What does the research show?

Cerebrolysin is one of the most extensively studied neuropeptide preparations, with a large international trial record across stroke, traumatic brain injury and dementia. However, the evidence is genuinely contested: several industry-sponsored RCTs report benefit, while large independent trials (such as the CASTA acute-stroke trial) and Cochrane meta-analyses have found insufficient evidence of meaningful benefit, and at least one Cochrane review flagged a signal for non-fatal serious adverse events. The honest summary is a multi-decade evidence base with positive industry data, an unconvinced independent literature, and an unresolved question.

EU legal status

Unusually for compounds in this encyclopedia, Cerebrolysin is an approved medicine in several European countries — it originated in Austria and is registered as a pharmaceutical in 40+ countries for stroke, TBI and dementia. It is not FDA-approved in the United States. Where it is approved it is a prescription medicine; where it is not, importing or using it outside that framework carries the usual legal and quality risks of unapproved injectables.